The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice.

We greatly appreciate a recent Editorial remarking the value of published case reports in drug safety and underlines the too often overlooked importance of reporting adverse drug reactions (i.e., adverse events suspectedly attributed to drug exposure) to a pharmacovigilance system. 1 Dermatologists are facing new challenges in real-world pharmacovigilance. On one hand, skin manifestations are increasingly documented with anticancer drugs and require multidisciplinary management since cutaneous adverse events have been proposed as potential biomarkers of drug efficacy, implying a delicate balance between timely interruption of the offender (with medical treatment) and early resumption to avoid cancer recurrence or progression.